Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

WHODAS Outcomes (ITT Analysis). by Mailma Costa de Almeida (22057684)

“…CTG showed a significant reduction in pain within 24 hours in the per-protocol analysis (Log-rank <i><i>p</i></i> = <i><i>0.04</i></i>). …”

Efficacy primary and secondary outcomes. by Mailma Costa de Almeida (22057684)

“…CTG showed a significant reduction in pain within 24 hours in the per-protocol analysis (Log-rank <i><i>p</i></i> = <i><i>0.04</i></i>). …”

Table 1_Influence of age and sex on the diagnostic accuracy of pleural fluid carcinoembryonic antigen for malignant pleural effusion: a post hoc analysis.docx by Dan-Ni Yang (17642947)

“…</p>Methods<p>We enrolled participants from a prospective cohort (SIMPLE) and a retrospective cohort (BUFF). …”

Supplementary Material for: Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study by figshare admin karger (2628495)

“…Hepatic steatosis index (HSI) and non-alcoholic fatty liver disease (NAFLD) liver fat score also decreased significantly (HSI: 44.7 ± 6.2 to 42.2 ± 5.8 p<0.001; NAFLD liver fat score: 2.12 ± 2.90 to 0.43 ± 1.91, p<0.001). …”

Table 1_Correlation between changes of amino acid spectrum and alopecia in patients with obesity undergoing bariatric surgery: a prospective cohort study.docx by Tingwen Wang (3927815)

Image 1_The impact of tumor burden score on prognosis in patients after radical resection of hepatocellular carcinoma: a single-center retrospective study.tif by Junzhang Huang (13237880)

“…Purpose<p>This study examines the relationship between tumor burden score (TBS) and survival and recurrence following radical resection of hepatocellular carcinoma through a cohort study conducted in the Guangxi population of China.…”

Data Sheet 1_Promoting the development and approval of new traditional Chinese medicines in China: a pooled analysis of data from 2013 to 2024.docx by Xiaohong Long (20871797)

“…Post-reform, there has been a gradual increase in the number of new TCMs, with a notably significant rise in ancient classic formulas. …”

Table 1_The impact of tumor burden score on prognosis in patients after radical resection of hepatocellular carcinoma: a single-center retrospective study.docx by Junzhang Huang (13237880)

“…Purpose<p>This study examines the relationship between tumor burden score (TBS) and survival and recurrence following radical resection of hepatocellular carcinoma through a cohort study conducted in the Guangxi population of China.…”

Table 1_Spontaneous neural activity alterations in medication-naïve primary blepharospasm: a resting-state functional magnetic resonance imaging study.docx by Hua-Liang Li (20812799)

Data Sheet 1_Immunotherapy for neuromyelitis optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituxim... by Jing Zhou (168494)

“…The annual relapse rate (ARR) significantly decreased after treatment with all four drugs. …”

Supplementary file 1_Effects of nitrogen addition on SOC in alpine grasslands of the Qinghai-Tibetan Plateau and adjacent mountain regions: a meta-analysis.docx by Yanhui Ye (22775894)

“…However, long-term additions promote C loss via soil acidification and a critical shift in the microbial community, notably a decreased fungal-to-bacterial ratio. …”

Dataset file. by Anthony Muyunga (21954899)

“…</p><p>Conclusion</p><p>One in every six elderly persons living with HIV may have a probable anxiety disorder. Being unemployed, having a family history of mental health disorders, having stigma and having inadequate family support were significantly associated with having a probable anxiety disorder. …”

Supplementary Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer by Matthew T. Campbell (15096440)

“…<p>Flow cytometry of immune cells from serially collected blood samples with evidence of significant decrease in circulating NK cells in: A) Metastatic renal cell carcinoma cohort. …”